Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)
South Korea flag South Korea · Delayed Price · Currency is KRW
10,160
+10 (0.10%)
At close: Sep 11, 2026

Ahn-Gook Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
21,6537,48116,8451,2906,8753,939
Depreciation & Amortization
9,3468,7787,6985,0234,9304,507
Loss (Gain) From Sale of Assets
216.93-46.41-13,216-17.13-28.25-138.65
Asset Writedown & Restructuring Costs
2.752.75219.98-37.78-
Loss (Gain) From Sale of Investments
-4,509-989.18-229.34-920.69889.36-2,033
Loss (Gain) on Equity Investments
1,547579.82-1,3521,6411,645-2,613
Provision & Write-off of Bad Debts
84.1576.64-83.27757.97129.7171.68
Other Operating Activities
6,997-269.038,1654,7475,4788,724
Change in Accounts Receivable
9,49630,2263,541-7,972-11,980-10,171
Change in Inventory
-6,657-8,710-10,008-12,861-4,497-3,969
Change in Accounts Payable
1,3173,505-4,9312,5692,5281,090
Change in Other Net Operating Assets
-123.265,049-1,7354,415-4,2191,964
Operating Cash Flow
39,37145,6834,914-1,3281,7881,472
Operating Cash Flow Growth
3.62%829.63%--21.49%-86.84%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-10,271-8,465-75,887-5,474-2,931-4,035
Sale of Property, Plant & Equipment
10.63611,83311,20115.542.09
Cash Acquisitions
-2,224-2,224----
Sale (Purchase) of Intangibles
-3,467-131.34-395.05-708.77-735.39-1,028
Investment in Securities
3,383-1,584-10,93812,1679,9604,931
Other Investing Activities
-0-00-062.75
Investing Cash Flow
-13,169-12,398-75,38617,1866,4313,118

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--60,00010,000--
Long-Term Debt Repaid
--5,244-301.93-12,593-662.99-889.69
Net Debt Issued (Repaid)
-310.14-5,24459,698-2,593-662.99-889.69
Repurchase of Common Stock
-----554-435.14
Dividends Paid
-7,194-5,001-2,500-2,500-2,511-2,521
Other Financing Activities
---0---
Financing Cash Flow
-7,504-10,24457,198-5,093-3,728-3,846

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
307.7663.62127.648.0877.69136.61
Net Cash Flow
19,00623,104-13,14710,7724,569881.42

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
29,10037,218-70,972-6,802-1,143-2,563
Free Cash Flow Growth
-2.81%-----
Free Cash Flow Margin
8.43%12.13%-26.18%-2.91%-0.56%-1.57%
Free Cash Flow Per Share
2560.443274.68-6243.89-598.47-100.42-223.77
Levered Free Cash Flow
22,49637,633-82,4724,4911,732-988.07
Unlevered Free Cash Flow
24,12739,355-80,5954,5811,832-915.05

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
2,6102,8072,665976.99662.47121.11
Cash Income Tax Paid
1,1625,461652.732,921713.85101.29
Change in Working Capital
4,03330,070-13,134-13,849-18,168-11,086